Matches in SemOpenAlex for { <https://semopenalex.org/work/W2519703640> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- W2519703640 abstract "OBJECTIVE:Retrospective study of intrathecal rituximab (IT-R) use. BACKGROUND:Intravenous rituximab is widely used in diffuse large B-cell lymphoma but has poor CNS penetration. Single agent IT-R has been shown to be safe; however, the efficacy, as well as feasibility and safety in combination with other chemotherapies have not been characterized.METHODS:Retrospective review of IT-R treated patients at Memorial Sloan Kettering Cancer Center.RESULTS:Thirty-nine patients were included. The median age was 60 years and median KPS was 69 (range 20-90). N=17 patients had primary CNS lymphoma (PCNSL) and N=22 had secondary CNS lymphoma (SCNSL). Previously received treatments included R-MPV (N=14) and other IT treatments in N=11; 5 patients with PCNSL had never received treatment. CSF involvement was present in N=29 patients prior to IT-R. IT-R was given twice weekly at 25 mg in 1-42 doses with a median duration of 8 weeks. IT-R was given most commonly with high-dose methotrexate (N=27) and/or IV rituximab (N=29) based treatments; 10 patients received other concomitant intrathecal agents. Radiotherapy was part of the regimen in 3 patients. Seven underwent cytarabine consolidation and nine received stem-cell transplant. IT-R was well tolerated with brief, grade 1-2 possibly related toxicities, one grade 3 Ommaya infection and one grade 3 meningitis. Complete or partial response was attained in PCNSL (82[percnt]) and SCNSL (68[percnt]). Among 29 patients with CSF involvement, 22 achieved a cytologic response, at a median time of 8 weeks. The median PFS in recurrent PCNSL was 7m (range 1-23+) and in SCNSL it was 5m. The OS was 23m and 7m, respectively.CONCLUSIONS:IT-R use combined with a variety of treatments was feasible with minimal associated toxicities. We observed high response rates in these patients with poor prognoses, including in the CSF. The overall contribution of IT-R requires validation in randomized studies. Disclosure: Dr. Umemura has nothing to disclose. Dr. Omuro has received personal compensation for activities with Stemline, Novartis, and Bristol-Myers Squibb." @default.
- W2519703640 created "2016-09-23" @default.
- W2519703640 creator A5033053766 @default.
- W2519703640 creator A5033270808 @default.
- W2519703640 date "2016-04-05" @default.
- W2519703640 modified "2023-09-23" @default.
- W2519703640 title "Incorporating Intra-Thecal Rituximab into Chemotherapy Regimens for CNS Lymphoma (P6.281)" @default.
- W2519703640 hasPublicationYear "2016" @default.
- W2519703640 type Work @default.
- W2519703640 sameAs 2519703640 @default.
- W2519703640 citedByCount "0" @default.
- W2519703640 crossrefType "journal-article" @default.
- W2519703640 hasAuthorship W2519703640A5033053766 @default.
- W2519703640 hasAuthorship W2519703640A5033270808 @default.
- W2519703640 hasConcept C126322002 @default.
- W2519703640 hasConcept C141071460 @default.
- W2519703640 hasConcept C167135981 @default.
- W2519703640 hasConcept C2776694085 @default.
- W2519703640 hasConcept C2778041864 @default.
- W2519703640 hasConcept C2779338263 @default.
- W2519703640 hasConcept C2779384505 @default.
- W2519703640 hasConcept C2780653079 @default.
- W2519703640 hasConcept C2781059491 @default.
- W2519703640 hasConcept C2781173314 @default.
- W2519703640 hasConcept C2781393001 @default.
- W2519703640 hasConcept C2781413609 @default.
- W2519703640 hasConcept C71924100 @default.
- W2519703640 hasConcept C90924648 @default.
- W2519703640 hasConceptScore W2519703640C126322002 @default.
- W2519703640 hasConceptScore W2519703640C141071460 @default.
- W2519703640 hasConceptScore W2519703640C167135981 @default.
- W2519703640 hasConceptScore W2519703640C2776694085 @default.
- W2519703640 hasConceptScore W2519703640C2778041864 @default.
- W2519703640 hasConceptScore W2519703640C2779338263 @default.
- W2519703640 hasConceptScore W2519703640C2779384505 @default.
- W2519703640 hasConceptScore W2519703640C2780653079 @default.
- W2519703640 hasConceptScore W2519703640C2781059491 @default.
- W2519703640 hasConceptScore W2519703640C2781173314 @default.
- W2519703640 hasConceptScore W2519703640C2781393001 @default.
- W2519703640 hasConceptScore W2519703640C2781413609 @default.
- W2519703640 hasConceptScore W2519703640C71924100 @default.
- W2519703640 hasConceptScore W2519703640C90924648 @default.
- W2519703640 hasLocation W25197036401 @default.
- W2519703640 hasOpenAccess W2519703640 @default.
- W2519703640 hasPrimaryLocation W25197036401 @default.
- W2519703640 hasRelatedWork W2219644495 @default.
- W2519703640 hasRelatedWork W2322522387 @default.
- W2519703640 hasRelatedWork W2526392872 @default.
- W2519703640 hasRelatedWork W2550172655 @default.
- W2519703640 hasRelatedWork W2551210684 @default.
- W2519703640 hasRelatedWork W2557062468 @default.
- W2519703640 hasRelatedWork W2560244195 @default.
- W2519703640 hasRelatedWork W2582455958 @default.
- W2519703640 hasRelatedWork W2590007275 @default.
- W2519703640 hasRelatedWork W2914656225 @default.
- W2519703640 hasRelatedWork W2979333626 @default.
- W2519703640 hasRelatedWork W2979571225 @default.
- W2519703640 hasRelatedWork W3029503939 @default.
- W2519703640 hasRelatedWork W3040245446 @default.
- W2519703640 hasRelatedWork W3095565402 @default.
- W2519703640 hasRelatedWork W3097178658 @default.
- W2519703640 hasRelatedWork W3117647026 @default.
- W2519703640 hasRelatedWork W3165372441 @default.
- W2519703640 hasRelatedWork W823885555 @default.
- W2519703640 hasRelatedWork W919457599 @default.
- W2519703640 hasVolume "86" @default.
- W2519703640 isParatext "false" @default.
- W2519703640 isRetracted "false" @default.
- W2519703640 magId "2519703640" @default.
- W2519703640 workType "article" @default.